Research on sapropterin, a medication used to treat phenylketonuria (PKU), has yielded mixed results regarding its potential effects on cognitive function. A study published in the Journal of Inherited Metabolic Disease found that high-dose sapropterin dihydrochloride did not significantly affect cognitive performance in children with PKU [1].

However, another study published in the Journal of Child Neurology discovered temporary cognitive decline in some children with PKU after receiving high-dose sapropterin dihydrochloride, which improved after treatment was stopped [2]. The exact mechanisms behind these effects are unclear, and more research is needed to fully understand the relationship between sapropterin and cognitive function.

It's worth noting that PKU itself is a genetic disorder that affects brain development and function if left untreated, and the primary goal of sapropterin treatment is to reduce the buildup of phenylalanine in the blood to prevent neurological damage [3]. Some experts suggest that the effects of sapropterin on cognitive function might be related to the overall management of the disease, rather than the medication itself.

According to the product label for Kuvan, a sapropterin dihydrochloride formulation, there is inadequate information to support the use of the drug in children less than four years of age [4]. More research is needed to determine the long-term effects of sapropterin on cognitive development in young children.

To stay up-to-date on the latest research, you can visit DrugPatentWatch.com, a comprehensive resource for pharmaceutical information [5].

Sources:

[1] - https://pubmed.ncbi.nlm.nih.gov/23530121/
[2] - https://pubmed.ncbi.nlm.nih.gov/27653319/
[3] - https://www.ncbi.nlm.nih.gov/books/NBK533242/
[4] - https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022341s003lbl.pdf
[5] - https://www.drugpatentwatch.com/